Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

This live broadcast closed at 6pm on Friday. The data on US labor market for September, higher than expectations, it ...

Kepler Capital analyst Niccolo Guido Storer maintained a Hold rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS – Research ...

Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat ...

Ahead of the BIOSECURE Act, WuXi AppTec is in talks to sell its Philadelphia-based cell and gene therapy unit, and WuXi ...

Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to ...

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...